Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2010-05-21
2011-10-11
Saoud, Christine J (Department: 1647)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007210, C436S501000, C530S300000, C530S350000
Reexamination Certificate
active
08034575
ABSTRACT:
RTP801 represents a unique gene target for hypoxia-inducible factor-1 (HIF-1). Down-regulation of the mTOR pathway activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of RTP801.The present invention relates to screening systems utilizing RTP801 and/or RTP801 interactors to and/or RTP801 biological activity, to drug candidates identified by such screening systems, and to the use of such drug candidates in the treatment of various disorders.
REFERENCES:
patent: 6455674 (2002-09-01), Einat et al.
patent: 6555667 (2003-04-01), Einat et al.
patent: 6673549 (2004-01-01), Furness et al.
patent: 6740738 (2004-05-01), Einat et al.
patent: 2002/0119463 (2002-08-01), Faris
patent: 2002/0137077 (2002-09-01), Hopkins et al.
patent: 2003/0104973 (2003-06-01), Einat et al.
patent: 2003/0108871 (2003-06-01), Kaser
patent: 2003/0165864 (2003-09-01), Lasek et al.
patent: 2006/0240022 (2006-10-01), Klippel-Giese et al.
patent: 2007/0149467 (2007-06-01), Lee
patent: 2007/0178090 (2007-08-01), Sukumar et al.
patent: 2007/0185017 (2007-08-01), Aggarwal et al.
patent: 2007/0224201 (2007-09-01), Wu et al.
patent: 2007/0281326 (2007-12-01), Wechsler et al.
patent: 2008/0014599 (2008-01-01), Wechsler et al.
patent: 2008/0064650 (2008-03-01), Feinstein et al.
patent: 2008/0269156 (2008-10-01), Feinstein et al.
patent: 234602 (2001-04-01), None
patent: 19816395 (1999-10-01), None
patent: 1 394 274 (2004-03-01), None
patent: 1 104 808 (2005-09-01), None
patent: 1 580 263 (2005-09-01), None
patent: 2003-259877 (2003-09-01), None
patent: WO 00/14283 (2000-03-01), None
patent: WO 00/61620 (2000-10-01), None
patent: WO 00/77022 (2000-12-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 01/77289 (2001-10-01), None
patent: WO 01/12659 (2001-12-01), None
patent: WO 01/96391 (2001-12-01), None
patent: WO 02/31111 (2002-04-01), None
patent: WO 02/46465 (2002-06-01), None
patent: WO 02/068579 (2002-09-01), None
patent: WO 02/101075 (2002-12-01), None
patent: WO 03/010205 (2003-02-01), None
patent: WO 03/025138 (2003-03-01), None
patent: WO 03/029271 (2003-04-01), None
patent: WO 03/087768 (2003-10-01), None
patent: WO 03/101283 (2003-12-01), None
patent: WO 2004/018999 (2004-03-01), None
patent: WO 2004/045545 (2004-06-01), None
patent: WO 2004/048520 (2004-06-01), None
patent: WO 2004/048938 (2004-06-01), None
patent: WO 2004/060270 (2004-07-01), None
patent: WO 2005/016000 (2005-02-01), None
patent: WO 2005/044981 (2005-05-01), None
Elena Feinstein and Rami Skaliter, U.S. Appl. No. 11/655,636, filed Jan. 18, 2007 pending claims.
Birukova AA, et al. (2004) “Novel role of microtubules in thrombin induced endothelial barrier dysfunction,”FASEB J. December;18(15):1879-90.
Brafman, A. et al., (2004) “Inhibition of Oxygen-Induced Retinopathy In RTP801-Deficient Mice,”Investigative Opthalmology&Visual Science, 45(10): 3796-3805.
Brugarolas, J. et al., (2004) “Regulation of mTOR Function In Response to Hypoxia By REDD1 And The TSC1/TSC2 Tumor Suppressor Complex,”Genes&Development, 18: 2893-2904.
Bulinski JC, et al. (1991) “Stabilization of post-translational modification of microtubules during cellular morphogenesis,”Bioessays. June;13(6):285-93.
Cai SL, et al. (2006) “Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning,”J Cell Biol. Apr. 24;173(2):279-89.
Choi JH, (2000) “TOR signaling regulates microtubule structure and function,”Curr Biol. Jul. 13;10(14):861-4.
Corradetti MN, (2005)The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem. Mar. 18;280(11):9769-72.
Cuaz-perolin et al., (2004) REDD2 gene is upregulated by modified LDL or hypoxia and mediates human macrophage cell death. Arterioscler Thromb Vasc Biol. October;24(10):1830-5. Epub Aug. 12, 2004.
Ellisen LW. (2005) Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle. November;4(11):1500-02.
Ellisen, L. et al., (2002) “REDD1, A Developmentally Regulated Transcriptional Target of p63 and p53, Links p63 To Regulation of Reactive Oxygen Species,”Molecular Cell, 10: 995-1005.
Frolov, A. et al., (2003) “Response Markers and the Molecular Mechanisms of Action of Gleevec in Gastrointestinal Stromal Tumors,”Molecular Cancer Therapeutics, 2: 699-709.
Gau CL, et al. (2005) “Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways,”Mol Cancer Ther. June;4(6):918-26.
Honore S, et al. (2005): Understanding microtubule dynamics for improved cancer therapy. Cell Mol Life Sci. December;62(24):3039-56. Review.
Jiang X, Yeung RS (2006) “Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway,”Cancer Res. May 15;66(10):5258-69.
Jozwiak J, et al. (2005): Positive and negative regulation of TSC2 activity and its effects on downstream effectors of the mTOR pathway. Neuromolecular Med. 7(4):287-96.
Kim, J. et al., (2003) “Identification of Amyloid β-peptide Responsive Genes by cDNA Microarray Technology: Involvement ofRTP8O1In Amyloid β-peptide Toxicity,”Experimental and Molecular Medicine, 35(5): 403-411.
Lal, A. et al., (2001) “Transcriptional Response to Hypoxia in Human Tumors,”Journal of the National Cancer Institute, 93(17): 1337-1343.
Lee, M. et al., (2004) “Sp1-Dependant Regulation of the RTP801 Promoter and Its Application To Hypoxia-Inducible VEGF Plasmid For Ischemic Disease,”Pharmaceutical Research, 21(5) : 736-741.
Li Y, et all. (2005) “Measurements of TSC2 GAP Activity Toward Rheb,”Methods Enzymol. 407:46-54.
Liu H, et al. (2006):. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. Proc Natl Acad Sci U S A. Mar. 14;103(11):4134-9.
Peris L, et al. (2006) “Job D. Tubulin tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at microtubule plus ends,”J Cell Biol. Sep. 11;174(6):839-49.
Pisani et al., (2005) SMHS1 is involved in oxidative/glycolytic-energy metabolism balance of muscle fibers. Biochem Biophys Res Commun Jan. 28;326(4):788-93.
Rangasamy, R. et al., (2004) “Genetic Ablation of Nrf2 Enhances Susceptibility To Cigarrette Smoke-Induced Emphysema in Mice,”The Journal of Clinical Investigation, 114(9): 1248-1259.
Reiling, J. and Hafen, E., (2004) “The Hypoxia-Induced Paralogs Scylla and Charybdis Inhibit Growth by Down-Regulating S6K Activity Upstream of TSC In Drosophila,”Genes&Development, 18:2879-2892.
Richard, D. et al., (2000) “Nonhypoxic Pathway Mediates the Induction of Hypoxia-Inducible Factor lα in Vascular Smooth Muscle Cells,”The Journal of Biological Chemistry, 275(35):26765-26771.
Sarbassov DD, et al. (2006): Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.Mol Cell. Apr. 21;22(2):159-68.
Schwarzer, R. et al., (2005) “REDD1 Integrates Hypoxia-Mediated Survival Signaling Downstream of Phosphatidylinositol 3-kinase,”Oncogene, 24: 1138-1149.
Shoshani, T. et al., (2002) “Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene,RTP801, Involved in Apoptosis,”Molecular and Cell Biology, 22(7): 2283-2293.
Sofer A, et al. (2005): Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol Cell Biol. July;25(14):5834-45.
Strausberg, R. et al., (2002) “Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences,”Proceedings of the National Academy of Sciences of the United States of America, 99(26): 16899-16903.
Tee AR, et al. (2003): Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. Aug. 5;13(15):1259-68.
Wang, J. an
Feinstein Elena
Mett Igor
Wechsler Roni
Cooper & Dunham LLP
Lockard Jon M
Quark Pharmaceuticals Inc.
Saoud Christine J
White John P.
LandOfFree
Screening systems utilizing RTP801 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening systems utilizing RTP801, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening systems utilizing RTP801 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4284424